Hologic Completes Acquisition of Biotheranostics | 合法醫療器材資訊網

2021年1月5日 — Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million. Read More

2021年2月22日 — Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market ... MARLBOROUGH, Mass.--(BUSINESS WIRE)-- ... Read More

Hologic has now acquired Biotheranostics, developer of two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer ... Read More

2021年2月23日 — Biotheranostics' tests are PCR-based gene expression tests that have been validated in large studies in areas of oncology with unmet needs and ... Read More

2021年1月6日 — Hologic to acquire Biotheranostics for $230M ... Hologic (NSDQ:HOLX) announced that it agreed to acquire molecular diagnostic test maker ... Read More

2021年1月6日 — Hologic announced late Tuesday its acquisition of Biotheranostics for $230 million, marking the second tuck-in for the medical device maker less ... Read More

2021年2月22日 — Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market. -- Breast Cancer Index™ Added to National ... Read More

2021年2月22日 — Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market ... MARLBOROUGH, Mass.--(BUSINESS WIRE)-- ... Read More

2021年2月26日 — 26, 2021–Hologic has completed its acquisition of Biotheranostics for about $230 million. Biotheranostics develops and markets Breast Cancer ... Read More